First Patient in CytoDyn's Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.